Targeting Cancer‐Associated Fibroblasts: Eliminate or Reprogram?
Cancer Science · 2025-03 · 116 (3) · 613-621
DOI: 10.1111/cas.16443 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Science, online erschienen am 02.01.2025. Verfasst von Masaya Yamazaki und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Carcinogenesis, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan. Hauptthemen laut MEDLINE: Cancer-Associated Fibroblasts, Tumor Microenvironment, Neoplasms, Cellular Reprogramming. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Fusion Oriented REsearch for disruptive Science and Technology, Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Cancer‐associated fibroblasts (CAFs) are key components of the tumor microenvironment (TME). Given their various roles in tumor progression and treatment resistance, CAFs are promising therapeutic targets in cancer. The elimination of tumor‐promoting CAFs has been investigated in various animal models to determine whether it effectively suppresses tumor growth. Based on recent evidence, several simple strategies have been proposed to eliminate tumor‐promoting CAFs and attenuate these features. In addition, attention has focused on the critical role that CAFs play in the immunosuppressive TME. Therefore, the functional reprogramming of CAFs in combination with immune checkpoint inhibitors has also been investigated as a possible therapeutic approach. However, although potential targets in CAFs have been widely characterized, the plasticity and heterogeneity of CAFs complicate the understanding of their properties and present difficulties for clinical application. Moreover, the identification of tumor‐suppressive CAFs highlights the necessity for the development of therapeutic approaches that can distinguish and switch between tumor‐promoting and tumor‐suppressive CAFs in an appropriate manner. In this review, we introduce the origins and diversity of CAFs, their role in cancer, and current therapeutic strategies aimed at targeting CAFs, including ongoing clinical evaluations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Carcinogenesis, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
- International Research Center of Medical Sciences (IRCMS), Kumamoto University, Kumamoto, Japan.
ORCID-Profile: Masaya Yamazaki, Takatsugu Ishimoto
Förderung
- Fusion Oriented REsearch for disruptive Science and Technology
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
- Chugai Foundation for Innovative Drug Discovery Science
- The Kao Foundation for Arts and Sciences
- Suzuken Memorial Foundation
- Pancreas Research Foundation of Japan
- The Shinnihon Foundation of Advanced Medical Treatment Research
Zitieren
APA
Yamazaki, M., & Ishimoto, T. (2025). Targeting Cancer‐Associated Fibroblasts: Eliminate or Reprogram?. Cancer Science, 116(3), 613-621. https://doi.org/10.1111/cas.16443
Vancouver
Yamazaki M, Ishimoto T. Targeting Cancer‐Associated Fibroblasts: Eliminate or Reprogram?. Cancer Science. 2025;116(3):613-621. doi:10.1111/cas.16443
BibTeX
@article{Yamazaki2025,
author = {Yamazaki, Masaya and Ishimoto, Takatsugu},
title = {Targeting Cancer‐Associated Fibroblasts: Eliminate or Reprogram?},
journal = {Cancer Science},
year = {2025},
volume = {116},
number = {3},
pages = {613--621},
doi = {10.1111/cas.16443}
}
EUVIMED